COMPARISON · NO RANKING

Anti-CD20 Antibody Comparison: Rituximab Biosimilars

Background

About CD20 and Rituximab biosimilars

CD20 (also known as MS4A1) is a B-lymphocyte surface protein expressed on cells from late pre-B-cell through to memory B-cell stages of differentiation. It does not appear on plasma cells or early stem cells, which is why it has become a high-value target for monoclonal antibody therapies in B-cell lymphomas, chronic lymphocytic leukaemia and autoimmune disorders.

Rituximab is the first-in-class anti-CD20 monoclonal antibody, a chimeric mouse/human IgG1 originally developed by IDEC Pharmaceuticals and marketed as Rituxan® (Genentech/Roche). It binds a large extracellular loop of CD20 and triggers B-cell depletion through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct apoptosis.

Research-grade Rituximab biosimilars are recombinant antibodies that incorporate the same variable region as the therapeutic Rituximab, formatted for laboratory use. They are not clinical-grade and not approved for human treatment, but they are valuable for biosimilar comparability studies, CDC and ADCC functional assays, CAR-T construct validation, and B-cell research generally.

This page compares the four Anti-CD20 Rituximab biosimilars with publicly listed catalog numbers from major suppliers. They share the Rituximab variable region but differ in host species, format and which applications each vendor has validated. The matrix below shows facts; the buyer applies their own criteria.

Specs side-by-side

Anti-CD20 Antibody Specifications Compared

Abcamab275973
Host
Rabbit
Reactivity
Human
Format
Rabbit IgG chimeric, Rituximab variable region
Applications
IHC-P, WB, Flow Cytometry
Citations
18
View on Abcam ↗
BioLegendQA20A02
Host
Human
Reactivity
Human
Format
Ultra-LEAF™ low-endotoxin recombinant IgG
Applications
Functional Assay, CDC, Flow Cytometry
Citations
42
View on BioLegend ↗
Cell Signaling Technology91213
Host
Human
Reactivity
Human
Format
Human recombinant IgG1, Rituximab variable region
Applications
Flow Cytometry, IHC, WB, IF
Citations
64
View on Cell Signaling Technology ↗
Creative BiolabsTAB-016
Host
Mouse
Reactivity
Human
Format
Chimeric mouse/human IgG1 kappa
Applications
Neutralisation, ELISA, IF, IP, Functional Assay, Flow Cytometry, WB
Citations
142
View on Creative Biolabs ↗
Applications

Validated Applications for Each Anti-CD20 Antibody

Which products are documented as validated for which application. Sourced from each vendor's product page. A check means the vendor lists that application; a dash means it is not listed (which is not the same as not working; the vendor simply hasn't validated for it).

ApplicationAbcamBioLegendCell Signaling TechnologyCreative Biolabs
Flow Cytometry4 of 4
WB3 of 4
—
IHC1 of 4
———
IHC-P1 of 4
———
IF2 of 4
——
IP1 of 4
———
ELISA1 of 4
———
Functional Assay2 of 4
——
CDC1 of 4
———
Neutralisation1 of 4
———

Counts above each row tell you how many of the 4 antibodies are documented for that application. Useful when narrowing to your workflow.

How to read this

Choosing the Right Anti-CD20 Antibody for Your Workflow

These rules teach you which column in the table to weight. They do not pick a product for you.

  • In-vivo or murine model work
    Compare the Host species and Format columns. Mouse-host and chimeric biosimilars behave differently in murine models than human-host recombinants.
  • Clinical-workflow IHC on FFPE tissue
    Compare the Applications column for IHC-P validation and the Host species column. Rabbit-host antibodies are often preferred for IHC-FFPE staining workflows.
  • Functional assays (CDC, ADCC, neutralisation)
    Compare the Format and Applications columns. Low-endotoxin or LEAF-formatted products avoid confounding effects in functional readouts.
  • Published validation depth
    Compare the Citations column. Higher citation counts mean more peer-reviewed publications using that exact product, which reduces methodological risk.
  • Multi-application validation in one antibody
    Compare the Applications column for the longest validated list. A single antibody validated across more applications reduces SKU count and improves cross-experiment comparability.
FAQ

Anti-CD20 Antibody Buyer Questions

Do all four antibodies bind the same epitope on CD20?

Yes. Abcam ab275973, BioLegend QA20A02, Cell Signaling 91213, and Creative Biolabs TAB-016 all incorporate the Rituximab variable region, which binds a specific extracellular loop of CD20. That is the same epitope as therapeutic Rituximab. Apparent affinity and effector function can differ across products because of host-specific glycosylation, constant region choice and purification format, but the target binding site is identical across all four. That is what makes this comparison genuinely apples-to-apples.

What is the practical difference between Ultra-LEAF and standard format?

BioLegend QA20A02 ships in the Ultra-LEAF™ low-endotoxin format, purified to typically <0.1 EU/μg. That matters in functional assays where contaminating LPS would activate TLR4 and confound the readout in CDC, ADCC, cell stimulation, and in-vivo experiments. Abcam ab275973, Cell Signaling 91213, and Creative Biolabs TAB-016 are standard research-grade preparations that are not endotoxin-tested by default. For non-functional applications like IHC, WB or basic flow staining, the difference is largely irrelevant. For functional or in-vivo work, it is material.

Which of these is documented for IHC on FFPE tissue?

Two of the four list IHC validation. Abcam ab275973 is explicitly validated for IHC-P (formalin-fixed paraffin-embedded sections), the standard choice for clinical-style pathology workflows. Cell Signaling 91213 lists general IHC validation but does not specify FFPE-only protocols. BioLegend QA20A02 and Creative Biolabs TAB-016 are not documented for IHC by their vendors. Documentation is not a hard limit. Researchers commonly validate antibodies for additional applications in their own protocols.

Which is suitable for in-vivo or low-endotoxin functional work?

BioLegend QA20A02 is specifically formatted (Ultra-LEAF™) for in-vitro functional assays with controlled endotoxin. Creative Biolabs TAB-016 lists Neutralisation as a documented application, which implies functional utility but does not specify endotoxin levels. Abcam ab275973 and Cell Signaling 91213 are not formatted or validated for endotoxin-sensitive use. For any in-vivo or functional experiment, verify each vendor's endotoxin specification directly before purchase.

Why does Creative Biolabs TAB-016 use a mouse host when the others use rabbit or human?

Therapeutic Rituximab is itself a mouse/human chimera. Its variable region is murine in origin, fused to human IgG1 constant regions. Creative Biolabs TAB-016 preserves this original chimeric format. The other vendors graft the same Rituximab variable region onto different scaffolds: Abcam ab275973 uses a rabbit IgG chimera, while Cell Signaling 91213 and BioLegend QA20A02 produce fully human recombinant IgG. This affects ADCC effector function in human systems, secondary antibody compatibility in multiplex flow or IHC panels, and behaviour in murine models.

How should I interpret the citation count differences across these products?

Approximate citation counts as of May 2026: 18 for Abcam ab275973, 42 for BioLegend QA20A02, 64 for Cell Signaling 91213, and 142 for Creative Biolabs TAB-016. Higher counts often reflect product age (older products accumulate citations longer) and how aggressively each vendor encourages catalog-number reporting in publications. Citation count is one signal. It does not directly measure performance for your specific application. Format, host species, validated applications and endotoxin status often matter more.

Are any of these clinical-grade or approved for human therapeutic use?

No. All four are research-use only (RUO). None are GMP-manufactured or approved for human treatment. Therapeutic Rituximab (Rituxan®, Truxima®, Ruxience® and other approved clinical biosimilars) remains the only option for patient therapy. These research-grade biosimilars are intended for in-vitro studies, mechanism research, biosimilar comparability characterisation, antibody engineering, and pre-clinical animal work. Never clinical use.
References

CD20 and Rituximab references

Authoritative sources for the target biology and the therapeutic Rituximab that these biosimilars are derived from.

Procurement

Compare specs, then quote any of these

BioLynkr can route enquiries to any of the 4 vendors above. Submit one form and we handle the rest.